Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
Top Cited Papers
- 15 April 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (8) , 2670-2676
- https://doi.org/10.1182/blood.v99.8.2670
Abstract
Hemophilia B is an X-linked coagulopathy caused by absence of functional coagulation factor IX (FIX). Using adeno-associated virus (AAV)–mediated, liver-directed gene therapy, we achieved long-term (> 17 months) substantial correction of canine hemophilia B in 3 of 4 animals, including 2 dogs with an FIX null mutation. This was accomplished with a comparatively low dose of 1 × 1012 vector genomes/kg. Canine FIX (cFIX) levels rose to 5% to 12% of normal, high enough to result in nearly complete phenotypic correction of the disease. Activated clotting times and whole blood clotting times were normalized, activated partial thromboplastin times were substantially reduced, and anti-cFIX was not detected. The fourth animal, also a null mutation dog, showed transient expression (4 weeks), but subsequently developed neutralizing anti-cFIX (inhibitor). Previous work in the canine null mutation model has invariably resulted in inhibitor formation following treatment by either gene or protein replacement therapies. This study demonstrates that hepatic AAV gene transfer can result in sustained therapeutic expression in a large animal model characterized by increased risk of a neutralizing anti-FIX response.Keywords
This publication has 37 references indexed in Scilit:
- Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null MutationMolecular Therapy, 2001
- Risk and Prevention of Anti-factor IX Formation in AAV-Mediated Gene Transfer in the Context of a Large Deletion of F9Molecular Therapy, 2001
- Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 miceGene Therapy, 2001
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in LiverMolecular Therapy, 2000
- Advances toward Gene Therapy for Hemophilia at the MillenniumHuman Gene Therapy, 1999
- Use of a Liver-Specific Promoter Reduces Immune Response to the Transgene in Adenoviral VectorsHuman Gene Therapy, 1999
- Induction of cytokine production in naive CD4+ T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells☆, ☆☆Gastroenterology, 1999
- In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient DogsScience, 1993